FDA has now approved 8 FoB products corresponding to 6 branded biologics: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm Amjevita and Cyltezo—the two approved FoBs for Humira—have not been launched due to ABBV’s patent estate (#msg-134970085).